|
Biotech
Funds Feeling the Pinch
May
11, 2008--Biotech
companies and/or their products may represent an attractive means
to bolster Pharma pipelines. Despite their position as potentially
attractive targets, across
Europe, biotech funds have seen their assets under management decline
from $18.7 billion at the end of 2001 to $4.8 billion as of
February, according to data from Lipper Feri. Net outflows
increased to $1.4 billion last year. In the
US
, healthcare and biotech funds saw net outflows of $5.4 billion in
2007, according to EPFR Global, although remaining assets under
management are $55 billion. Financial
Times
|
